Terms: = Skin cancer AND CXCR4, D2S201E, 7852, ENSG00000121966, P61073, NPYY3R, NPY3R, HM89, NPYRL, LESTR, HSY3RR, LCR1, fusin, WHIM, NPYR, FB22, CD184
177 results:
1. Exploring the Interplay of RUNX2 and cxcr4 in Melanoma Progression.
Dalle Carbonare L; Minoia A; Vareschi A; Piritore FC; Zouari S; Gandini A; Meneghel M; Elia R; Lorenzi P; Antoniazzi F; Pessoa J; Zipeto D; Romanelli MG; Guardavaccaro D; Valenti MT
Cells; 2024 Feb; 13(5):. PubMed ID: 38474372
[TBL] [Abstract] [Full Text] [Related]
2. Targeting the CXCL12/cxcr4 pathway to reduce radiation treatment side effects.
Chaudary N; Hill RP; Milosevic M
Radiother Oncol; 2024 May; 194():110194. PubMed ID: 38447871
[TBL] [Abstract] [Full Text] [Related]
3. Tozasertib activates anti-tumor immunity through decreasing regulatory T cells in melanoma.
Wang Q; Liu W; Zhou H; Lai W; Hu C; Dai Y; Li G; Zhang R; Zhao Y
Neoplasia; 2024 Feb; 48():100966. PubMed ID: 38237304
[TBL] [Abstract] [Full Text] [Related]
4. Has-miR-300-GADD45B promotes melanoma growth via cell cycle.
Chen L; Fang C; Yuan X; Liu M; Wu P; Zhong L; Chen Z
Aging (Albany NY); 2023 Dec; 15(23):13920-13943. PubMed ID: 38070141
[TBL] [Abstract] [Full Text] [Related]
5. A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of whim syndrome.
McDermott DH; Velez D; Cho E; Cowen EW; DiGiovanna JJ; Pastrana DV; Buck CB; Calvo KR; Gardner PJ; Rosenzweig SD; Stratton P; Merideth MA; Kim HJ; Brewer C; Katz JD; Kuhns DB; Malech HL; Follmann D; Fay MP; Murphy PM
J Clin Invest; 2023 Oct; 133(19):. PubMed ID: 37561579
[TBL] [Abstract] [Full Text] [Related]
6. Differential Response of Mycosis Fungoides Cells to Vorinostat.
Bordeaux ZA; Reddy SV; Lee K; Lu W; Choi J; Miller M; Roberts C; Pollizzi A; Kwatra SG; Kwatra MM
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175780
[TBL] [Abstract] [Full Text] [Related]
7. Mavorixafor, an Orally Bioavailable cxcr4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma.
Andtbacka RHI; Wang Y; Pierce RH; Campbell JS; Yushak M; Milhem M; Ross M; Niland K; Arbeit RD; Parasuraman S; Bickley K; Yeung CC; Aicher LD; Smythe KS; Gan L
Cancer Res Commun; 2022 Aug; 2(8):904-913. PubMed ID: 36923305
[TBL] [Abstract] [Full Text] [Related]
8. Use of the benchmark-dose (BMD) approach to derive occupational exposure limits (OELs) for genotoxic carcinogens: N-nitrosamines.
Blum K; FitzGerald R; Wilks MF; Barle EL; Hopf NB
J Appl Toxicol; 2023 Aug; 43(8):1183-1200. PubMed ID: 36840679
[TBL] [Abstract] [Full Text] [Related]
9. The Role of Cytokines in the Metastasis of Solid Tumors to the Spine: Systematic Review.
Łabędź W; Przybyla A; Zimna A; Dąbrowski M; Kubaszewski Ł
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835198
[TBL] [Abstract] [Full Text] [Related]
10. A self-assembling cxcr4-targeted pyroptosis nanotoxin for melanoma therapy.
Zhao Z; Huang Y; Wang J; Lin H; Cao F; Li S; Li Y; Li Z; Liu X
Biomater Sci; 2023 Mar; 11(6):2200-2210. PubMed ID: 36745434
[TBL] [Abstract] [Full Text] [Related]
11. Vascular endothelial growth factor-C in activating vascular endothelial growth factor receptor-3 and chemokine receptor-4 in melanoma adhesion.
Hlophe YN; Joubert AM
J Cell Mol Med; 2022 Dec; 26(23):5743-5754. PubMed ID: 36398426
[TBL] [Abstract] [Full Text] [Related]
12. Silencing of SiX-4 enhances the chemosensitivity of melanoma cells to Cisplatin.
Vazirabad AF; Noorolyai S; Baghbani E; Mahboob S; Zargari F; Rahmani S; Sorkhabi A; Montazami N; Sameti P; Baradaran B
Pathol Res Pract; 2022 Dec; 240():154194. PubMed ID: 36370483
[TBL] [Abstract] [Full Text] [Related]
13. The involvement of a chemokine receptor antagonist CTCE-9908 and kynurenine metabolites in cancer development.
Nkandeu DS; Basson C; Joubert AM; Serem JC; Bipath P; Nyakudya T; Hlophe Y
Cell Biochem Funct; 2022 Aug; 40(6):608-622. PubMed ID: 35789495
[TBL] [Abstract] [Full Text] [Related]
14. Preclinical platforms to study therapeutic efficacy of human γδ T cells.
Ou L; Wang H; Huang H; Zhou Z; Lin Q; Guo Y; Mitchell T; Huang AC; Karakousis G; Schuchter L; Amaravadi R; Guo W; Salvino J; Herlyn M; Xu X
Clin Transl Med; 2022 Jun; 12(6):e814. PubMed ID: 35731974
[TBL] [Abstract] [Full Text] [Related]
15. High-Dimensional Analysis Reveals Distinct Endotypes in Patients With Idiopathic Inflammatory Myopathies.
Wilfong EM; Bartkowiak T; Vowell KN; Westlake CS; Irish JM; Kendall PL; Crofford LJ; Bonami RH
Front Immunol; 2022; 13():756018. PubMed ID: 35371068
[TBL] [Abstract] [Full Text] [Related]
16. Non-invasive detection and complementary diagnosis of liver metastases via chemokine receptor 4 imaging.
Yang H; Tan S; Qiao J; Xu Y; Gui Z; Meng Y; Dong B; Peng G; Ibhagui OY; Qian W; Lu J; Li Z; Wang G; Lai J; Yang L; Grossniklaus HE; Yang JJ
Cancer Gene Ther; 2022 Dec; 29(12):1827-1839. PubMed ID: 35145271
[TBL] [Abstract] [Full Text] [Related]
17. Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma.
Rindler K; Jonak C; Alkon N; Thaler FM; Kurz H; Shaw LE; Stingl G; Weninger W; Halbritter F; Bauer WM; Farlik M; Brunner PM
Mol Cancer; 2021 Sep; 20(1):124. PubMed ID: 34583709
[TBL] [Abstract] [Full Text] [Related]
18. Current Challenges in Targeting Tumor Desmoplasia to Improve the Efficacy of Immunotherapy.
Kasperska A; Borowczak J; Szczerbowski K; Stec E; Ahmadi N; Szylber Ł
Curr Cancer Drug Targets; 2021; 21(11):919-931. PubMed ID: 34525931
[TBL] [Abstract] [Full Text] [Related]
19. Pro-pigmentary action of 5-fluorouracil through the stimulated secretion of CXCL12 by dermal fibroblasts.
Liao ZK; Hu SH; Han BY; Qiu X; Jiang S; Lei TC
Chin Med J (Engl); 2021 Sep; 134(20):2475-2482. PubMed ID: 34507320
[TBL] [Abstract] [Full Text] [Related]
20. Overexpression of chemokine receptor cxcr4 predicts lymph node metastatic risk in patients with melanoma: A systematic review and meta-analysis.
Alimohammadi M; Rahimi A; Faramarzi F; Alizadeh-Navaei R; Rafiei A
Cytokine; 2021 Dec; 148():155691. PubMed ID: 34464923
[TBL] [Abstract] [Full Text] [Related]
[Next]
